Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at D. Boral Capital

Stock analysts at D. Boral Capital assumed coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a note issued to investors on Monday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $32.00 price target on the stock.

Several other equities analysts have also recently issued reports on the company. Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $5.00 to $4.00 in a research report on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, November 11th. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.80.

Compass Therapeutics Trading Down 0.7 %

CMPX stock opened at $1.50 on Monday. The business has a 50 day simple moving average of $1.64 and a 200-day simple moving average of $1.41. The company has a market capitalization of $206.38 million, a P/E ratio of -4.05 and a beta of 0.89. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. Research analysts predict that Compass Therapeutics will post -0.35 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

Hedge funds have recently modified their holdings of the business. Barclays PLC grew its holdings in Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after acquiring an additional 112,614 shares during the period. Geode Capital Management LLC boosted its position in shares of Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after purchasing an additional 19,095 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Compass Therapeutics during the 3rd quarter worth $37,000. The Manufacturers Life Insurance Company acquired a new position in shares of Compass Therapeutics during the 3rd quarter worth $79,000. Finally, Intech Investment Management LLC purchased a new position in shares of Compass Therapeutics in the 3rd quarter valued at about $30,000. 68.43% of the stock is owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.